Leukemia & Lymphoma最新文献_第9页

Routine magnetic resonance central nervous system imaging may be avoided in high-risk systemic diffuse large B-cell lymphoma with negative cerebrospinal fluid analyses. 脑脊液分析阴性的高危系统性弥漫性大b细胞淋巴瘤可避免常规中枢神经系统磁共振成像。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-01-14 DOI: 10.1080/10428194.2025.2451725

Rory Bennett, Manu Juneja, Mary Ann Anderson, Adrian Minson, Kirsten Herbert, Graham J Lieschke, Andrew W Roberts, Kylie D Mason, John F Seymour, Michael Dickinson

引用次数: 0

Unusually indolent CML: a stable non-responder without complete cytogenetic remission for 30 years including 17 years on tyrosine kinase inhibitor therapy. 异常惰性CML：稳定无反应，30年未完全细胞遗传学缓解，包括17年酪氨酸激酶抑制剂治疗。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-01-12 DOI: 10.1080/10428194.2024.2448716

Qiudan Shen, Guilin Tang, Fadi G Haddad, Wenbo Chen, Wei J Wang, Wei Wang, Qing Wei, L Jeffrey Medeiros, Shimin Hu

引用次数: 0

Effects of SCT genetic polymorphisms on methotrexate concentrations and toxicities in Chinese children with acute lymphoblastic leukemia. SCT基因多态性对中国急性淋巴细胞白血病儿童甲氨蝶呤浓度和毒性的影响。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-01-11 DOI: 10.1080/10428194.2025.2451059

Miao Li, Dan-Qi Zhao, Xiao-Yan Kong, Shu-Mei Wang

{"title":"Effects of SCT genetic polymorphisms on methotrexate concentrations and toxicities in Chinese children with acute lymphoblastic leukemia.","authors":"Miao Li, Dan-Qi Zhao, Xiao-Yan Kong, Shu-Mei Wang","doi":"10.1080/10428194.2025.2451059","DOIUrl":"https://doi.org/10.1080/10428194.2025.2451059","url":null,"abstract":"Solute carrier (SLC) transporters play a crucial role in facilitating the cellular uptake of various anticancer drugs, such as methotrexate (MTX). This study aimed to analyze the impact of nonsynonymous single nucleotide polymorphisms (SNPs) in SLC19A1, SLCO1B1, and SLCO1B3 on MTX exposure, toxicities, and prognosis in 148 patients with acute lymphoblastic leukemia (ALL). The SLCO1B3 rs7311358 polymorphism was significantly associated with the median dose-normalized MTX concentrations at 24 h (p < .05). There were significant differences in the proportions of patients with serum MTX levels >40 µmol/L at 24 h among SLC19A1 rs1051266 GG, GA, and AA genotype carriers (29.0, 24.7, and 6.2%, respectively, p < .05). The SLC19A1 rs1051266 G > A polymorphism also displayed significant associations with hematological (p < .05) and hepatic toxicities (p < .01). Our findings indicate that the analysis of SNPs in solute carrier transporters (SCTs) could offer valuable insights into the interpatient variability of MTX pharmacokinetics and toxicities in ALL children.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-11"},"PeriodicalIF":2.2,"publicationDate":"2025-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142971356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Interim-PET predicts progression-free survival in stage IV Hodgkin lymphoma treated with upfront brentuximab vedotin-AVD. 中期pet预测先期brentuximab vedotin-AVD治疗的IV期霍奇金淋巴瘤的无进展生存期。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-01-11 DOI: 10.1080/10428194.2024.2446609

Chiara Rusconi, Angelica Barone, Andrea Visentin, Benedetta Bianchi, Vittorio Ruggero Zilioli, Andrea Bernardelli, Sara Iadecola, Edoardo Olivari, Francesca Gaia Rossi, Manuel Gotti, Caterina Cecchetti, Benedetta Puccini, Silvia Franceschetti, Alfredo Molteni, Sara Steffanoni, Fabrizio Marino, Anna Vanazzi, Anna Guidetti, Michele Merli, Federico Mazzon, Alfredo Marchetti, Alessandro Cellini, Cristina Muzi, Rosalba Miceli, Carlo Visco, Alessandro Re, Paolo Corradini

{"title":"Interim-PET predicts progression-free survival in stage IV Hodgkin lymphoma treated with upfront brentuximab vedotin-AVD.","authors":"Chiara Rusconi, Angelica Barone, Andrea Visentin, Benedetta Bianchi, Vittorio Ruggero Zilioli, Andrea Bernardelli, Sara Iadecola, Edoardo Olivari, Francesca Gaia Rossi, Manuel Gotti, Caterina Cecchetti, Benedetta Puccini, Silvia Franceschetti, Alfredo Molteni, Sara Steffanoni, Fabrizio Marino, Anna Vanazzi, Anna Guidetti, Michele Merli, Federico Mazzon, Alfredo Marchetti, Alessandro Cellini, Cristina Muzi, Rosalba Miceli, Carlo Visco, Alessandro Re, Paolo Corradini","doi":"10.1080/10428194.2024.2446609","DOIUrl":"https://doi.org/10.1080/10428194.2024.2446609","url":null,"abstract":"Brentuximab vedotin (BV) plus doxorubicin, vinblastine and dacarbazine (AVD) demonstrated to improve survival compared to ABVD as frontline treatment of advanced stage Hodgkin Lymphoma (HL). We retrospectively collected data of 99 stage IV HL patients treated off-protocol with BV-AVD to evaluate the predictive role of interim-PET. Median age was 36 years (range: 18-82); 83.8% patients completed all planned 6 cycles and 80.8% obtained complete response at PET6. Median follow-up was 14.4 months; 1-year progression-free survival (PFS) and overall survival were 84.1% (CI 95%: 77-91.9) and 96.9% (CI 95%: 93.6-100). PET2-negative patients had a superior 1-year PFS compared to PET2-positive patients: 90.0% vs 46.2% (p < .001). At multivariable analysis, PET2 positivity retained unfavorable statistical significance in PFS: HR 4.6 (95% CI: 1.4-15.2, p = .009). BV-AVD was confirmed to be effective in a real-world setting, while PET2-positive patients displayed a remarkably lower 1-year PFS than that previously reported and might benefit from a PET-driven approach.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-9"},"PeriodicalIF":2.2,"publicationDate":"2025-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142965409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

gneSeqCOO: a novel method for classifying diffuse large B-cell lymphoma cell of origin based on bulk tumor RNA sequencing profiles. gneSeqCOO：一种基于肿瘤整体RNA测序谱的弥漫性大b细胞淋巴瘤细胞起源分类的新方法。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-01-10 DOI: 10.1080/10428194.2024.2446613

Will Harris, Yi Cao, Franck Morschhauser, Gilles Salles, Yanwen Jiang, Alessia Bottos, Georg Lenz, Christopher R Bolen

{"title":"gneSeqCOO: a novel method for classifying diffuse large B-cell lymphoma cell of origin based on bulk tumor RNA sequencing profiles.","authors":"Will Harris, Yi Cao, Franck Morschhauser, Gilles Salles, Yanwen Jiang, Alessia Bottos, Georg Lenz, Christopher R Bolen","doi":"10.1080/10428194.2024.2446613","DOIUrl":"https://doi.org/10.1080/10428194.2024.2446613","url":null,"abstract":"The cell of origin (COO) classification is an expression-based tumor algorithm identifying molecular subtypes of diffuse large B-cell lymphoma (DLBCL) with distinct prognostic characteristics. Traditional immunohistochemical methods for classifying COO subtypes have poor concordance and limited prognostic value in frontline DLBCL. In contrast, RNA-based metrics like the NanoString Lymphoma Subtyping Test (LST) define more robust subtypes with validated prognostic associations. This study introduces gneSeqCOO, an algorithm using bulk RNA Sequencing (RNASeq) profiles of individual tumor biopsies for COO classification based on a fixed reference. This method produced consistent per-sample results and was robust to variation in RNA quality and sequencing bias. Validation in >1000 DLBCL samples showed high concordance with the NanoString LST assay, even in cohorts containing only one COO subtype. gneSeqCOO presents a robust and versatile alternative to existing assays, potentially reducing the need for additional samples where RNASeq was already generated. The package is available at https://github.com/Genentech/gneSeqCOO.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-8"},"PeriodicalIF":2.2,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142962026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Frontline immunotherapeutic combination strategies in adult B-cell acute lymphoblastic leukemia: reducing chemotherapy intensity and toxicity and harnessing efficacy. 成人b细胞急性淋巴细胞白血病的一线免疫治疗联合策略：降低化疗强度和毒性，提高疗效。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-01-10 DOI: 10.1080/10428194.2025.2449582

Jayastu Senapati, Hagop Kantarjian, Diane Habib, Fadi G Haddad, Nitin Jain, Nicholas J Short, Elias Jabbour

{"title":"Frontline immunotherapeutic combination strategies in adult B-cell acute lymphoblastic leukemia: reducing chemotherapy intensity and toxicity and harnessing efficacy.","authors":"Jayastu Senapati, Hagop Kantarjian, Diane Habib, Fadi G Haddad, Nitin Jain, Nicholas J Short, Elias Jabbour","doi":"10.1080/10428194.2025.2449582","DOIUrl":"https://doi.org/10.1080/10428194.2025.2449582","url":null,"abstract":"Using immunotherapeutic agents like inotuzumab ozogamicin (InO), blinatumomab, or chimeric antigen receptor T (CAR T)-cell therapy in frontline adult B-cell acute lymphoblastic leukemia (B-ALL) therapy is promising. These agents are mostly well tolerated and have different toxicity profiles than conventional chemotherapy, enabling their combination with chemotherapy. Additionally, they have often been shown to overcome the traditional adverse ALL risk features. Recently blinatumomab was approved as part of consolidation therapy in MRD negative B-ALL; however, a significant proportion of patients had progressed or relapsed before reaching the timepoint of blinatumomab administration. Including InO/blinatumomab from induction onwards could induce earlier and deeper remissions. Modifications of dosing and administration schedules, as with the fractionated InO schedule with low-intensity chemotherapy, and subcutaneous blinatumomab, appear to reduce the toxicity and improve the anti-ALL efficacy. CAR T-cell therapies like brexucabtagene autoleucel as a consolidation approach have shown positive outcomes. The feasibility of using CAR T-cells to reduce the need for long-drawn maintenance and the need for allogeneic hematopoietic stem cell transplantation (HSCT) are questions of ongoing clinical trials. Newer generation CAR T-cell products like obecabtagene autoleucel appear as effective and safer. Better disease monitoring through next generation sequencing based measurable residual disease analysis could identify patients where treatment intensification including HSCT, or deintensification, is suitable.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-12"},"PeriodicalIF":2.2,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142950844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Early intervention with ruxolitinib improves spleen response in patients with myelofibrosis. 鲁索利替尼早期干预可改善骨髓纤维化患者的脾反应。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-01-09 DOI: 10.1080/10428194.2024.2447884

Pankit Vachhani, Paola Guglielmelli, Jennifer Repp, J E Hamer-Maansson, Evan Braunstein, Haifa Kathrin Al-Ali

引用次数: 0

Prephase steroid use and association with dose delays and outcomes in a real-world cohort of older adults treated for diffuse large B-cell lymphoma. 弥漫性大b细胞淋巴瘤老年患者的前期类固醇使用及其与剂量延迟和预后的关系

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-01-08 DOI: 10.1080/10428194.2025.2450091

Alexander R Vartanov, Jill S Hasler, Elizabeth A Handorf, Zachary A K Frosch

引用次数: 0

Prognostic factors in chronic lymphocytic leukaemia - the old, the new and the future. 慢性淋巴细胞白血病的预后因素-旧的，新的和未来。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-01-07 DOI: 10.1080/10428194.2024.2449214

Sean McKeague, Constantine Tam

引用次数: 0

Variance in development of early and late cardiotoxicities in patients with lymphoma and myeloma receiving CAR T-cell therapies. 接受CAR - t细胞治疗的淋巴瘤和骨髓瘤患者早期和晚期心脏毒性发展的差异

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-01-07 DOI: 10.1080/10428194.2024.2448713

Eli Grunblatt, Zhiying Meng, Abigail S Baldridge, Nikita P Patel, Alexander Stanisic, Matthew J Feinstein, Anjali Rao, Leo I Gordon, Jane N Winter, Shuo Ma, Jayesh Mehta, Seema Singhal, Reem Karmali, Nausheen Akhter

{"title":"Variance in development of early and late cardiotoxicities in patients with lymphoma and myeloma receiving CAR T-cell therapies.","authors":"Eli Grunblatt, Zhiying Meng, Abigail S Baldridge, Nikita P Patel, Alexander Stanisic, Matthew J Feinstein, Anjali Rao, Leo I Gordon, Jane N Winter, Shuo Ma, Jayesh Mehta, Seema Singhal, Reem Karmali, Nausheen Akhter","doi":"10.1080/10428194.2024.2448713","DOIUrl":"https://doi.org/10.1080/10428194.2024.2448713","url":null,"abstract":"Cardiovascular adverse events (CVAEs) are recognized complications of chimeric antigen receptor (CAR) T-cell therapies. However, data are lacking regarding subtypes of adverse events that develop in patients with different malignancies, and little is known about the timeframe in which different cardiotoxicities are most likely to occur post-CAR T-cell therapies. In this study, 211 patients, including 138 lymphoma patients and 66 myeloma patients who received CAR T-cell therapies were retrospectively identified. Of these, 42 patients (19.9%) developed CVAEs post-treatment. Myeloma patients predominantly experienced heart failure while lymphoma patients predominantly experienced arrhythmia. Severe CVAEs were observed even at >12 months post-treatment. Lower baseline global longitudinal strain was significantly associated with development of post-CAR T-cell therapy CVAEs in both lymphoma and myeloma patients. These findings highlight the spectra of post-CAR T-cell cardiotoxicities in lymphoma and myeloma patients and the importance of echocardiography for pretreatment risk stratification and long-term surveillance.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-11"},"PeriodicalIF":2.2,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142950872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0